Working… Menu
Trial record 1 of 75 for:    Louis Lopez
Previous Study | Return to List | Next Study

Prospective Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the FLEX Scoring Catheter Plus DCB (FORTEZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03676842
Recruitment Status : Terminated (Low enrollment)
First Posted : September 19, 2018
Last Update Posted : April 19, 2021
Information provided by (Responsible Party):
VentureMed Group Inc.

Brief Summary:
Prospective, single-center, single-arm, non-randomized study to assess the safety and efficacy of the FLEX Scoring Catheter in patients with atherosclerotic peripheral artery disease in the superficial femoral and popliteal arteries.

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Combination Product: FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the FLEX Scoring Catheter Plus DCB
Actual Study Start Date : October 11, 2018
Actual Primary Completion Date : September 23, 2020
Actual Study Completion Date : September 23, 2020

Arm Intervention/treatment
Experimental: FLEX Scoring Catheter plus DCB
This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
Combination Product: FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB
Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB

Primary Outcome Measures :
  1. Technical feasibility of the FLEX Scoring Catheter [ Time Frame: Through study completion: Approximately 12 months ]
    Evaluation of the technical feasibility of using the FLEX Scoring Catheter during the endovascular treatment of critical SFA or popliteal artery lesions.

Secondary Outcome Measures :
  1. Absence of lesion restenosis [ Time Frame: 6 and 12 months ]
    Defined by PSVR ≥ to 2.5 at duplex scan

  2. Change in Rutherford Class of symptom [ Time Frame: 6 and 12 months ]
  3. Change in ankle-brachial index (ABI) [ Time Frame: 6 and 12 months ]
  4. Absence of clinically driven target vessel revascularization [ Time Frame: 12 months ]
  5. Major adverse events (MAE) [ Time Frame: at procedure, 6 months, and 12 months ]
  6. Proportion of luminal gain [ Time Frame: at procedure ]
  7. Proportion of stent implantation [ Time Frame: at procedure ]
  8. Proportions and classifications of dissections [ Time Frame: at procedure ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women of child-bearing potential must have a negative test within 7 days of the initial procedure
  • Patient or patient's legal representative has been informed of the nature of the study, agrees to participate and comply with all follow-up visits, and has signed the informed consent.
  • Patient is eligible for standard surgical repair in the target limb if necessary.
  • Patient has Rutherford Clinical Category estimated as 2-6.
  • A life expectancy >1 year.

Angiographic Inclusion Criteria:

  • Target lesion(s) is located within the SFA and/or the popliteal arteries.
  • Target lesion has >70% stenosis by visual assessment.
  • The reference vessel diameter is between 4-6 mm.
  • One long or multiple serial lesions.
  • de novo or non-stented re-stenotic lesions.
  • At least one BTK artery patent to the ankle.
  • Successful treatment of iliac inflow stenosis to the target limb. Stenosis can be treated during the same procedure using standard angioplasty and/or stenting but atherectomy is excluded. The inflow lesion(s) must be treated first, before consideration of treatment of the target lesion. Subject can be enrolled if the treated inflow lesion(s) results in <30% residual stenosis and no evidence of embolization or significant complications.

Exclusion Criteria:

  • Rutherford Clinical Category 1.
  • Previously implanted ipsilateral femoral or popliteal stent.
  • Evidence of aneurysm or acute thrombus in the target vessel.
  • Patients with previous bypass surgery in the lower target extremity.
  • Planned major amputation, above the ankle, of either limb.
  • Patient has significant stenosis or occlusion of inflow tract not successfully treated (>30% residual stenosis and/or significant complication of the procedure)
  • History of any open surgical procedure within the past 30 days
  • Planned endovascular or vascular surgery procedure within 14 days prior to the ATK procedure, except to treat the inflow vessels on the day of the procedure, or within the next 30 days after the ATK procedure on the target limb.
  • Patient has an allergy to contrast medium that cannot be adequately pretreated.
  • Episode of acute limb ischemia within the past 30 days.
  • Patient has systemic infection with positive blood cultures/bacteremia within one week
  • Patient has hypercoagulable disorder.
  • Patient is contraindicated for antiplatelet, anticoagulant, or thrombolytic therapy.
  • Myocardial infarction within 30 days prior to enrollment.
  • History of stroke or TIA within 90 days prior to enrollment.
  • Patient has acute or chronic renal disease (i.e., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L)
  • Patient is pregnant or breastfeeding
  • Patient is participating in another research study of a device, medication, which could, in the opinion of the investigator, affect the results of this study.
  • Patient has other medical, social, or psychological problems that in the opinion of the investigator, would preclude them from receiving this treatment and the procedure and or participating in evaluations pre- and post-treatment.
  • Thrombolysis of the target lesion within 72 hours prior to the initial procedure, where complete resolution of the thrombus was not achieved.
  • Known allergies to both antiplatelet, aspirin, or heparin.
  • History of neutropenia, coagulopathy, or thrombocytopenia that was unexplained or is considered to be a risk for reoccurrence.
  • Platelet count less than 80,000/uL
  • Patient requires general anesthesia for procedure.
  • Patient requires dialysis.

Angiographic Exclusion Criteria:

  • Acute Total Occlusions; evidence of acute thrombus formation by angiography.
  • Severe calcification of target lesion described as circumferential calcium and >50% of lesion length.
  • Sub-intimal access required.
  • Inability to cross the lesion with a guidewire.
  • Atherectomy in the target lesion, target artery or for inflow treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03676842

Layout table for location information
United States, Indiana
Saint Joseph Hospital
Fort Wayne, Indiana, United States, 46802
Sponsors and Collaborators
VentureMed Group Inc.
Layout table for investigator information
Principal Investigator: Louis Lopez, MD Allen County Cardiology
Layout table for additonal information
Responsible Party: VentureMed Group Inc. Identifier: NCT03676842    
Other Study ID Numbers: The FORTEZ Study
First Posted: September 19, 2018    Key Record Dates
Last Update Posted: April 19, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases